Despite initially encouraging response to hormone therapy, prostate tumors finally develop a resistant phenotype and progress to a life-threatening disease. Critically involved in the mechanisms of therapy resistance and tumor progression is the androgen receptor, the central mediator of the proliferation and survival effects of androgens, and the target of endocrine therapy. There is mounting evidence that alteration of androgen signaling and function enables tumor cells to survive and adapt to hormone deprivation, resulting in autonomous activation of growth-promoting downstream targets. Changes include increased expression, gain of function mutations, activation of ligand-independent stimulation mechanisms, and altered expression of and interaction with co-modulatory proteins. A profound understanding of the pivotal changes underlying prostate cancer progression will be the key to the development of more efficient hormone therapy and novel treatment strategies for prostate cancer patients.
INTRODUCTION
The prostate gland is dependent on androgen hormones. It develops and grows under the influence of androgens, and their permanent stimulation is required for maintenance and function in the adult organ. Prostate tumors share this hormone-dependence with nonmalignant prostate tissue, at least in the early stages of tumor development. Since the pioneering work of Huggins, who first described this dependency, this forms the basis for the treatment of inoperable prostate cancer by hormone ablation (1). Withdrawal of androgens and inhibition of androgen signal transduction by anti-androgens stop proliferation and induce programmed cell death (apoptosis) in prostate tumor cells, allowing control of tumor growth until therapy resistance is developing.
The central molecule for mediation of androgen function and the target for endocrine therapy of prostate cancer is the androgen receptor (AR), a ligand-activated transcription factor and member of the superfamily of nuclear receptors. This receptor also is in the center of the mechanism enabling prostate tumor cells to escape therapy. In the last decade of prostate cancer research, several such mechanisms involving AR function have been uncovered. We still do not have a detailed picture of all of the underlying molecular mechanisms, but the emerging picture gives us invaluable clues for improving currently used prostate cancer therapy and developing new treatment concepts. The importance of the AR and AR signaling in prostate cancer progression is illustrated by the recent finding that alterations in this pathway are the only consistent change in gene profiling studies eluci-dating the mechanism of prostate tumor progression (2). Amplifications of the AR gene occur in approximately one-third of tumors escaping endocrine therapy (3,4).
AR STRUCTURE AND FUNCTION IN THE PROSTATE
The androgen hormone dihydrotestosterone (DHT) is the principal regulator of prostate development and growth during embryonal development and puberty (5). In the adult prostate, it is required for maintenance of tissue homeostasis and secretory function. The circulating steroid hormone, testosterone, diffuses into the cells and is there converted by the 5-α reductase enzymes to the more potent androgen, DHT (6) . DHT and other androgen hormones present in the prostate cells bind to a high-affinity binding protein required for mediating their effects, the AR. It is a member of the superfamily of nuclear receptors, its closest relatives are the progesterone, glucocorticoid, and the other steroid hormone receptors (7, 8) . Binding of androgen hormones triggers activation of the receptor to a transcription factor that interacts with and regulates the activity of gene promoters containing androgen-responsive elements (AREs). Activation involves a cascade of activation processes and the interaction with other components, such as co-regulatory proteins and proteins of the cellular transcription machinery.
The AR is encoded by a single gene on the long arm of the X chromosome spanning approx 180 kb (see gene atlas at: www.dsi.univ-paris5.fr/genatlas/fiche.php?n=5328) and is inherited in an X-linked fashion. The gene shows the typical structure of the nuclear receptor genes, with eight exons encoding the large N-terminal domain, a central DNA-binding domain composed of two zinc finger elements, a hinge region, and the C-terminal ligand-binding domain (9-11) (Fig. 1) . The AR gene promoter is characterized by a short GC-box and a homopurin stretch, but lacks TATA and CAAT boxes typical for many eukaryotic genes (12, 13) . Binding sites for the transcription factor SP1 and a cAMPresponsive element were characterized (14, 15) . Two messenger RNA (mRNA) species are transcribed, the major one is 10 kb and the minor one is 7 kb in size (13). The difference is in the large 3' untranslated region that follows the open-reading frame. The receptor protein has 919 amino acids, however, because of two polymorphic triplet repeats in exon 1, one encoding a polyglutamine (CAG) repeat and the second encoding a polyglycine (GCN) repeat with variable lengths, the individual size can vary (16, 17) . Short triplet repeat regions seem to be associated with a moderately increased risk to develop prostate cancer (18) and extension beyond 40 repeats is the underlying cause of spinal and bulbar muscular atrophy (19) . The AR gene is a locus of frequent mutations (http//:www.mcgill.ca/ androgendb). Approximately 300 mutations have been identified, most of them in male pseudohermaphroditism patients with various degrees of androgen insensitivity caused by loss of AR function (20, 21) . Approximately 70 AR mutations have been identified in prostate cancer cell lines and specimens. Many cause the AR to acquire promiscuous properties and are described in Chapter 5.
Inactive AR is associated with heat shock proteins, and the binding of the hormone to the ligandbinding domain initiates a cascade transforming the AR into an active transcription factor. Activation includes dissociation of heat shock proteins, hyperphosphorylation, conformational changes, translocation into the nucleus, dimerization, and association with co-modulatory proteins (22) (23) (24) (25) . Activated AR then interacts with the cellular transcription machinery regulating transcription of genes through binding to AREs (26) . Gene regulation may be positive or negative depending on the promoter and cellular context (27) (28) (29) .
Activated AR interacts with chromatin through its two central zinc finger motifs that are held in place by four conserved cysteine side chains coordinated to a zinc ion (30, 31) . This domain is the most highly conserved region among the steroid receptors. Nuclear magnetic resonance and X-ray diffraction analysis revealed that the interaction with the DNA occurs through a helix that fits into the major DNA groove (30) (31) (32) . The N-terminal domain comprises approximately half of the protein and contains the activation function domain (AF)-1 . It brings about most of the transactivation activity, in contrast to other steroid receptors, the AF2 located in the C-terminus is weak in the AR (33-35) .
